Src
特异性亚型抑制剂
Src产品
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1021 |
Dasatinib (BMS-354825)Dasatinib (BMS-354825) 是一种新型有效的多靶点抑制剂,作用于Abl、Src和 c-Kit,在无细胞试验中IC50分别为 <1 nM、0.8 nM 和 79 nM。Dasatinib 可诱导自噬和凋亡并具有抗肿瘤的活性。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S1006 |
Saracatinib (AZD0530)Saracatinib (AZD0530)是一种有效的Src抑制剂,无细胞试验中IC50为2.7 nM,对c-Yes, Fyn, Lyn, Blk, Fgr和Lck也具有活性;但对Abl和EGFR (L858R和L861Q)活性较低。Saracatinib可诱导自噬。Phase 2/3。 |
![]() ![]() C and D, in vivo subcutaneous tumor growth curves (C) and tumor weight quantification of intersected subcutaneous tumor tissues (D) of Huh7 cells after stable LHBs expression under saracatinib treatment (25 mg/kg body weight daily for 4 weeks; n =18). *, P < 0.05. E and F,in vivo subcutaneous tumor growth curves (E) and tumor weight quantification of intersected subcutaneous tumor tissues (F) of SK-Hep1 cells after stable LHBs expression under saracatinib treatment (25 mg/kg body weight daily for 4 weeks; n = 18). *, P < 0.05. |
|
S1490 |
Ponatinib (AP24534)Ponatinib (AP24534)是一种新型有效的多靶点抑制剂,在无细胞试验中作用于Abl,PDGFRα,VEGFR2,FGFR1和Src,IC50分别为0.37 nM,1.1 nM,1.5 nM,2.2 nM和5.4 nM。Ponatinib (AP24534)可抑制自噬。 |
![]() ![]()
RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT. |
|
S1574 |
Doramapimod (BIRB 796)Doramapimod (BIRB 796)是一种泛p38 MAPK抑制剂,在无细胞试验中作用于p38α/β/γ/δ的IC50分别为38 nM,65 nM,200 nM 和520 nM,并且能够与p38α结合,在THP-1细胞中Kd为0.1 nM,比作用于JNK2选择性高330倍,对c-RAF,Fyn 和Lck具有较弱的抑制作用,对ERK-1,SYK,IKK2也有微弱抑制作用。 |
![]() ![]() Effect of blockade of p38 or MEK on MK2 activation following TLR stimulation in moDC. MoDC were pre-treated with p38 inhibitors SB203580 10 mM (S), BIRB0796 (B) 0.1 or 1.0 mM or MEK inhibitor UO126 10 mM (U) for 1hr followed by poly I:C/R848 stimulation for 30 min then Western blotted for p-MK2 with β-actin loading control.
|
|
S1014 |
Bosutinib (SKI-606)Bosutinib (SKI-606) 是一种新型的双重Src/Abl抑制剂,在无细胞试验中IC50分别为1.2 nM 和 1 nM。Bosutinib也可通过阻滞p-ERK、p-S6和p-STAT3的磷酸化来有效地降低PI3K/AKT/mTOR、MAPK/ERK和JAK/STAT3信号通路的活性。Bosutinib可促进自噬。 |
![]() ![]() A,IC50 of Bosutinib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. The effect of inhibitors is presented as the percentage of ANDV-induced permeability of inhibitor-treated monolayers 3 days postinfection and 30 min post-VEGF and FITC-dextran addition. B, VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for Fig. 1 at indicated times in the presence or absence of Bosutinib . |
|
S9826New |
TPX-0046TPX-0046 是一种新型 RET/SRC 抑制剂,在 Ba/F3 细胞增殖试验中,对RETG810R 的平均 IC50 为 17 nM。 |
||
S9620New |
Elzovantinib (TPX-0022)Elzovantinib (TPX-0022, CSF1R-IN-2) 是一种有效的 MET/CSF1R/SRC 抑制剂,IC50 分别为 0.14 nM、0.71 nM 和 0.12 nM。TPX-0022 在临床前模型中可调节肿瘤免疫微环境。 |
||
S6383New |
1-NM-PP11-NM-PP1 (PP1 Analog II, 1NM-PP1, analogue 9) 是一种有效的 Src 家族激酶的抑制剂,对 v-Src-as1 和 c-Fyn-as1 的IC50值分别为 4.3 nM 和 3.2 nM。1-NM-PP1 还可抑制 CDK2-as1、CAMKII-as1 和 c-Abl-as2,其IC50值分别为 5.0 nM、8.0 nM和 120 nM。 |
||
S1392 |
Pelitinib (EKB-569)Pelitinib (EKB-569) 是一种有效的,不可逆 EGFR 抑制剂,IC50为38.5 nM。Pelitinib (EKB-569) 还轻微抑制 Src、MEK/ERK 和 ErbB2 ,对应的IC50值分别为282 nM、800 nM和1255 nM。Phase2。 |
![]() ![]() HBMEC were preincubated with the indicated concentrations of either ErB1/2/4 inhibitor (Pelitinib; EKB-569), and cells were then infected for 4 h with the unencapsulated strain, MC58 siaD. The numbers of adherent (black bars) and invasive (gray bars) bacteria were determined in a gentamicin protection assay. The graphs show the percentages of adhesion and invasion of inhibitor-treated cells, relative to control cells (means 盨D of three independent experiments performed in duplicate). *, P < 0.05.
|
|
S1396 |
Resveratrol (SRT501)Resveratrol (SRT501, trans-Resveratrol)具有广泛靶点,包括环氧酶(如COX, IC50=1.1 μM)、脂肪氧合酶(LOC, IC50=2.7 μM)、sirtuins和其他蛋白质。它是一种天然的植物抗毒素,具有抗癌,抗炎,降血糖和其他有益心血管的作用。Resveratrol可诱导线粒体自噬、细胞自噬和自噬依赖性的凋亡。 |
![]() ![]() Cellular senescence and SIRT1 phosphorylation was monitored in PAECs (P2) incubated in DMEM containing HDL (50 mg/L), LDL (50 mg/L), or resveratrol (100 μM) for 24 hours. |
|
S2700 |
KX2-391 (Tirbanibulin)KX2-391 (Tirbanibulin) 是第一个临床Src抑制剂(拟肽类),靶向作用于Src的肽底物位点,在癌细胞系中GI50为9-60 nM。Phase 2。 |
![]() ![]() Images of typical cultures treated with the compounds and/or 500 pM BoNT/A. Cells were treated with the compounds for 30 min and then intoxicated with 500 pM BoNT/A for 4 h. Cells were then fixed and immunostained for neuron-specific b-III Tubulin (green) and Hoechst dye (nuclei; blue). |
|
S2202 |
NVP-BHG712NVP-BHG712是一种特异性的EphB4抑制剂,ED50为25 nM,区别于对VEGFR和EphB4的抑制,对c-Raf, c-Src和c-Abl也具有抑制活性,IC50分别为0.395 μM, 1.266 μM和1.667 μM。 |
![]() ![]() |
|
S1181 |
ENMD-2076ENMD-2076 选择性地作用于 Aurora A 和 Flt3,IC50分别为14 nM和1.86 nM,作用于Aurora A比作用于Aurora B选择性高25倍,对RET、SRC、NTRK1/TRKA、CSF1R/FMS、VEGFR2/KDR、FGFR和PDGFRα作用效果稍弱。ENMD-2076 可抑制各种人类实体瘤和造血癌细胞系的生长,其IC50值为0.025至0.7μM,可诱导凋亡和G2/M期停滞。Phase 2。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
S8032 |
PRT062607 (P505-15) HClPRT062607 (P505-15, BIIB057, PRT-2607)是一种新型的,高度选择性Syk抑制剂,无细胞试验中IC50为1 nM,作用于Syk比作用于Fgr,PAK5,Lyn,FAK,Pyk2, FLT3, MLK1 和Zap70选择性高80倍以上。 |
![]() ![]() Dectin-1 is involved in activation of NLRP3-inflammasome by Malassezia spp. IL-1b secretion from mature human mono-DCs incubated with Syk-inhibitors (piceatannol, R406 or P505), 1 h prior to exposure to medium, MSU, b-glucan, nigericin or live M. furfur (MOI = 10) was determined after 6 h by ELISA.
|
|
S7008 |
PP2PP2 (AG 1879, AGL 1879) 是一种Src家族激酶抑制剂,有效抑制Lck/Fyn,无细胞试验中IC50为4 nM/5 nM,作用于EGFR效果低100倍左右,对ZAP-70,JAK2和PKA没有活性。 |
![]() ![]() Inhibition of PLCG1 phosphorylation by the silencing of DopEcR, ErGPCR, and Gq and the addition of inhibitors of RTK and Src. 5 µM SU6668 (RTK inhibitor) and 20 µM PP2 (Src inhibitor) were added to the cells for 30 min treatment before the 20E stimulation.
|
|
S2622 |
PP121PP121是一种作用于PDGFR, Hck, mTOR, VEGFR2, Src和Abl的多靶点抑制剂,IC50分别为2 nM, 8 nM, 10 nM, 12 nM, 14 nM和18 nM,也抑制DNA-PK,IC50为60 nM。 |
![]() ![]() PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
|
|
S7060 |
PP1PP1 (AGL 1872, EI 275)是一种有效的Src选择性抑制剂,作用于Lck/Fyn时,IC50为5 nM/6 nM。 |
![]() ![]() Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for inhibitors at indicated times in the presence or absence of the kinase inhibitor PP1. The percent change in FITC-dextran over controls is presented as a measure of EC monolayer permeability. Data are derived from two independent experiments performed in triplicate with comparable results.
|
|
S4921 |
MNS (3,4-Methylenedioxy-β-nitrostyrene)MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)是一种酪氨酸激酶抑制剂,抑制Syk, Src和p97, IC50分别为2.5 μM, 29.3 μM和1.7 μM。 |
![]() ![]() WT mouse primary macrophages were untreated as control (lane 1) or treated with 0.1μg/ml E. coli LPS (lane 5-8), 10μM E-64 (lane 2 and 6), 250μM PMSF (lane 3 and 7), or 20μM MNS (lane 4 and 8). The cells were continuously cultured for 16 hrs. Extracts from whole cells or nuclei were separately purified and subjected to WB analysis with antibody against pERK2, LITAF, or actin/tubulin as control.
|
|
S7565 |
WH-4-023WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) 是一种有效的,口服具有活性的Lck/Src抑制剂,无细胞试验中IC50分别为2 nM 和 6 nM。对p38α和KDR的选择性低300倍以上,还能有效抑制SIK(对SIK1、2、3的IC50分别为10、22、60 nM)。 |
![]() ![]() (G-I) WB analysis of total LCK, LCK Y505, and Src Y416 expression in ALL-SIL, CCRF-CEM, and TALL-1. Cells were treated with DMSO only (Ctrl), dasatinib, bosutinib, nintedanib, or WH-4-023 overnight at the compound concentrations corresponding to the GI50 at 48 hr. Bos, bosutinib; Das, dasatinib; Nint, nintedanib; WH, WH-4-023.
|
|
S3226 |
Dehydroabietic acidDehydroabietic acid (DAA, DHAA) 是一种天然的二萜树脂酸,衍生自针叶植物(如 Pinus 和 Picea)通过抑制 Src、Syk 和 TAK1 介导的通路来产生抗炎活性。 |
||
S0918 |
Ginkgolic acid C17:1Ginkgolic acid C17:1 (GAC 17:1) 通过废除上游的 JAK2 和 Src 来抑制 STAT3 的组成性激活。Ginkgolic acid C17:1 可以诱导 PTEN 和 SHP-1 的大量表达。Ginkgolic acid C17:1 诱导肿瘤细胞凋亡。 |
||
S5254 |
Dasatinib hydrochlorideDasatinib hydrochloride (BMS-354825) is the hydrochloride salt form of dasatinib, an inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. |
||
S0020 |
RK 24466RK-24466 (KIN 001-51, Lck inhibitor C 8863, C8863)是一种有效的、选择性的 Lck 抑制剂,可抑制人Lck激酶的两种构建体,lck (64-509)和lckcd,对应的IC50值分别为小于0.001 μM和0.002 μM。 |
||
S6500 |
KX1-004KX1-004是一种非ATP竞争性的Src protein tyrosine kinase抑制剂,对Src-PTK的IC50值为40 μM。 |
||
S5548 |
7-Hydroxy-4-chromone7-Hydroxychromone is an inhibitor of Src kinase with IC50 of <300 μM. |
||
S8518 |
AD80AD80,一种多激酶抑制剂,对人源RET (c-RET)、BRAF、S6K和SRC活性较强,但对mTOR的活性比AD57或AD58弱。其对RET (c-RET)的IC50值为4 nM。 |
||
S7782 |
Dasatinib MonohydrateDasatinib Monohydrate (BMS-354825)是一种新型有效的多靶点抑制剂,作用于靶点Abl,Src 和 c-Kit,IC50分别为 <1 nM,0.8 nM 和 79 nM。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S8583 |
Repotrectinib (TPX-0005)Repotrectinib (TPX-0005) 是一种新型的ALK/ROS1/TRK抑制剂,对WT ALK、ALK(G1202R)、ALK(L1196M)的IC50分别为1.01 nM、1.26 nM、1.08 nM;同时也是一种有效的SRC抑制剂,IC50为5.3 nM。 |
||
S9643 |
DGY-06-116DGY-06-116 是一种不可逆的、选择性的 Src 的共价抑制剂,对应的IC50值为2.6 nM。 |
||
S2391 |
Quercetin (NSC 9221)Quercetin (NSC 9221, Sophoretin, C.I. 75720)是蔬菜水果和白酒中的天然黄酮类化合物,是一种体外重组Sirt1蛋白的激活剂同时也是PI3K抑制剂,IC50为2.4 – 5.4 μM。Quercetin 可诱导凋亡和保护性的自噬。Phase 4。 |
![]() ![]() After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of Quercetin for 3h,followed by 20-minute stimolation of 100ng/ml EGF. |
|
S7774 |
SU6656SU 6656 是一种选择性 Src 家族激酶抑制剂,对Src,Yes,Lyn,和 Fyn 的 IC50 分别为 280 nM,20 nM,130 nM,和 170 nM。 |
![]() ![]() (B) IP3 levels measured by ELISA in CD36OE and vector control of HepG2.2.15 and HepAD38 cells (n = 3) (*P < 0.05). (C) Src kinase inhibitor (SU6656) decreases cytosolic Ca2+ in CD36OE of HepG2.2.15 and HepAD38 cells. SU6656 or vehicle controls (DMSO) were added to the CD36OE of HepG2.2.15 and HepAD38 cells for 24 h, Cytosolic Ca2+ was measured after treatment using flow cytometry (n = 3) (*** p < 0.001). (D) Src kinase inhibitor (SU6656) overrides the higher HBV replication induced by CD36 overexpression. SU6656 or vehicle controls (DMSO) were added to the CD36 overexpression of HepG2.2.15 and HepAD38 cells for 96 h. HBV DNA were extracted and detected by real-time PCR (n = 4). (**P < 0.01 and*** p < 0.001). |
|
S6567 |
Src Inhibitor 1Src Inhibitor 1是Src和Lck的竞争性抑制剂,IC50分别为44 nM和88 nM。它也能抑制Csk和Yes。 |
||
S7743 |
CCT196969CCT196969是一种新型的、具有口服活性的pan-RAF抑制剂,同时具有抑制SRC的活性。它还能抑制LCK和p38 MAPKs。 |
||
S5617 |
Myristic AcidMyristic acid (Tetradecanoic acid) is a fatty acid that occurs naturally in some foods. Myristic acid inhibits the phosphorylation of poly E4Y by Src with an Ki of 35 μM. |
||
S0791 |
eCF506eCF506 是一种有效的、选择性的和口服生物利用的 Src tyrosine kinase 抑制剂,其IC50值小于0.5 nM。 |
||
S8161 |
ON123300ON123300是有效的多靶点激酶抑制剂,对CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), Fyn的IC50分别为3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM和11nM。 |
||
S6060 |
HPK1-IN-2HPK1-IN-2 是一种有效的和口服活性的 hematopoietic progenitor kinase-1 (HPK1, a serine/threonine Ste20-related protein kinase)、Lck 和 Flt3 的抑制剂,其IC50值分别为 <0.05 μM、<0.5 μM 和 <0.05 μM。HPK1-IN-2 具有抗肿瘤的活性。 |
||
S2213 |
AMG-47aAMG-47a是一种有效的、非选择性的 Lck kinase 抑制剂,IC50为3.4 uM,它还可抑制T细胞增殖。AMG-47a在抗CD3诱导的小鼠白介素2(IL-2)生产过程中表现出11mg/kg的抗炎活性(ED50)。 |
||
S1272 |
XL228XL228 是一种 protein kinase 的抑制剂,对于野生型ABL kinase、ABL T315I、Aurora A、IGF-1R、SRC 和 LYN的IC50值分别为5 nM、1.4 nM、3.1 nM、1.6 nM、6.1 nM和2 nM。 |
||
S2642 |
1-Naphthyl PP1(1-NA-PP1)1-Naphthyl PP1 (1-NA-PP 1)是一种高度选择性的、有效的 pan-PKD 抑制剂,对于PKD1、PKD2和PKD3的IC50值分别为154.6 nM、133.4 nM和109.4 nM。1-Naphthyl PP1是 Src family kinases (v-Src, c-Fyn) 和 the tyrosine kinase c-Abl 的选择性抑制剂, 对于v-Src、c-Fyn、c-Abl、CDK2和CAMK II的IC50值分别为1.0 μM、 0.6 μM、0.6 μM、18 μM 和 22 μM。 |
||
S8706 |
UM-164UM-164是一种高度有效的c-Src/p38双重抑制剂,对c-Src的结合常数Kd值为2.7 nM,也能抑制p38α和p38β。 |
||
S8321 |
MLR-1023MLR-1023 (Tolimidone, CP-26154)是Lyn kinase 激活剂,也是一种新型的insulin receptor 增强剂,在具有2型糖尿病的动物模型中使得葡萄糖稳态快速起效、并持久改善。 |
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1021 |
Dasatinib (BMS-354825)Dasatinib (BMS-354825) 是一种新型有效的多靶点抑制剂,作用于Abl、Src和 c-Kit,在无细胞试验中IC50分别为 <1 nM、0.8 nM 和 79 nM。Dasatinib 可诱导自噬和凋亡并具有抗肿瘤的活性。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S1006 |
Saracatinib (AZD0530)Saracatinib (AZD0530)是一种有效的Src抑制剂,无细胞试验中IC50为2.7 nM,对c-Yes, Fyn, Lyn, Blk, Fgr和Lck也具有活性;但对Abl和EGFR (L858R和L861Q)活性较低。Saracatinib可诱导自噬。Phase 2/3。 |
![]() ![]() C and D, in vivo subcutaneous tumor growth curves (C) and tumor weight quantification of intersected subcutaneous tumor tissues (D) of Huh7 cells after stable LHBs expression under saracatinib treatment (25 mg/kg body weight daily for 4 weeks; n =18). *, P < 0.05. E and F,in vivo subcutaneous tumor growth curves (E) and tumor weight quantification of intersected subcutaneous tumor tissues (F) of SK-Hep1 cells after stable LHBs expression under saracatinib treatment (25 mg/kg body weight daily for 4 weeks; n = 18). *, P < 0.05. |
|
S1490 |
Ponatinib (AP24534)Ponatinib (AP24534)是一种新型有效的多靶点抑制剂,在无细胞试验中作用于Abl,PDGFRα,VEGFR2,FGFR1和Src,IC50分别为0.37 nM,1.1 nM,1.5 nM,2.2 nM和5.4 nM。Ponatinib (AP24534)可抑制自噬。 |
![]() ![]()
RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT. |
|
S1574 |
Doramapimod (BIRB 796)Doramapimod (BIRB 796)是一种泛p38 MAPK抑制剂,在无细胞试验中作用于p38α/β/γ/δ的IC50分别为38 nM,65 nM,200 nM 和520 nM,并且能够与p38α结合,在THP-1细胞中Kd为0.1 nM,比作用于JNK2选择性高330倍,对c-RAF,Fyn 和Lck具有较弱的抑制作用,对ERK-1,SYK,IKK2也有微弱抑制作用。 |
![]() ![]() Effect of blockade of p38 or MEK on MK2 activation following TLR stimulation in moDC. MoDC were pre-treated with p38 inhibitors SB203580 10 mM (S), BIRB0796 (B) 0.1 or 1.0 mM or MEK inhibitor UO126 10 mM (U) for 1hr followed by poly I:C/R848 stimulation for 30 min then Western blotted for p-MK2 with β-actin loading control.
|
|
S1014 |
Bosutinib (SKI-606)Bosutinib (SKI-606) 是一种新型的双重Src/Abl抑制剂,在无细胞试验中IC50分别为1.2 nM 和 1 nM。Bosutinib也可通过阻滞p-ERK、p-S6和p-STAT3的磷酸化来有效地降低PI3K/AKT/mTOR、MAPK/ERK和JAK/STAT3信号通路的活性。Bosutinib可促进自噬。 |
![]() ![]() A,IC50 of Bosutinib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. The effect of inhibitors is presented as the percentage of ANDV-induced permeability of inhibitor-treated monolayers 3 days postinfection and 30 min post-VEGF and FITC-dextran addition. B, VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for Fig. 1 at indicated times in the presence or absence of Bosutinib . |
|
S9826New |
TPX-0046TPX-0046 是一种新型 RET/SRC 抑制剂,在 Ba/F3 细胞增殖试验中,对RETG810R 的平均 IC50 为 17 nM。 |
||
S9620New |
Elzovantinib (TPX-0022)Elzovantinib (TPX-0022, CSF1R-IN-2) 是一种有效的 MET/CSF1R/SRC 抑制剂,IC50 分别为 0.14 nM、0.71 nM 和 0.12 nM。TPX-0022 在临床前模型中可调节肿瘤免疫微环境。 |
||
S6383New |
1-NM-PP11-NM-PP1 (PP1 Analog II, 1NM-PP1, analogue 9) 是一种有效的 Src 家族激酶的抑制剂,对 v-Src-as1 和 c-Fyn-as1 的IC50值分别为 4.3 nM 和 3.2 nM。1-NM-PP1 还可抑制 CDK2-as1、CAMKII-as1 和 c-Abl-as2,其IC50值分别为 5.0 nM、8.0 nM和 120 nM。 |
||
S1392 |
Pelitinib (EKB-569)Pelitinib (EKB-569) 是一种有效的,不可逆 EGFR 抑制剂,IC50为38.5 nM。Pelitinib (EKB-569) 还轻微抑制 Src、MEK/ERK 和 ErbB2 ,对应的IC50值分别为282 nM、800 nM和1255 nM。Phase2。 |
![]() ![]() HBMEC were preincubated with the indicated concentrations of either ErB1/2/4 inhibitor (Pelitinib; EKB-569), and cells were then infected for 4 h with the unencapsulated strain, MC58 siaD. The numbers of adherent (black bars) and invasive (gray bars) bacteria were determined in a gentamicin protection assay. The graphs show the percentages of adhesion and invasion of inhibitor-treated cells, relative to control cells (means 盨D of three independent experiments performed in duplicate). *, P < 0.05.
|
|
S1396 |
Resveratrol (SRT501)Resveratrol (SRT501, trans-Resveratrol)具有广泛靶点,包括环氧酶(如COX, IC50=1.1 μM)、脂肪氧合酶(LOC, IC50=2.7 μM)、sirtuins和其他蛋白质。它是一种天然的植物抗毒素,具有抗癌,抗炎,降血糖和其他有益心血管的作用。Resveratrol可诱导线粒体自噬、细胞自噬和自噬依赖性的凋亡。 |
![]() ![]() Cellular senescence and SIRT1 phosphorylation was monitored in PAECs (P2) incubated in DMEM containing HDL (50 mg/L), LDL (50 mg/L), or resveratrol (100 μM) for 24 hours. |
|
S2700 |
KX2-391 (Tirbanibulin)KX2-391 (Tirbanibulin) 是第一个临床Src抑制剂(拟肽类),靶向作用于Src的肽底物位点,在癌细胞系中GI50为9-60 nM。Phase 2。 |
![]() ![]() Images of typical cultures treated with the compounds and/or 500 pM BoNT/A. Cells were treated with the compounds for 30 min and then intoxicated with 500 pM BoNT/A for 4 h. Cells were then fixed and immunostained for neuron-specific b-III Tubulin (green) and Hoechst dye (nuclei; blue). |
|
S2202 |
NVP-BHG712NVP-BHG712是一种特异性的EphB4抑制剂,ED50为25 nM,区别于对VEGFR和EphB4的抑制,对c-Raf, c-Src和c-Abl也具有抑制活性,IC50分别为0.395 μM, 1.266 μM和1.667 μM。 |
![]() ![]() |
|
S1181 |
ENMD-2076ENMD-2076 选择性地作用于 Aurora A 和 Flt3,IC50分别为14 nM和1.86 nM,作用于Aurora A比作用于Aurora B选择性高25倍,对RET、SRC、NTRK1/TRKA、CSF1R/FMS、VEGFR2/KDR、FGFR和PDGFRα作用效果稍弱。ENMD-2076 可抑制各种人类实体瘤和造血癌细胞系的生长,其IC50值为0.025至0.7μM,可诱导凋亡和G2/M期停滞。Phase 2。 |
![]() ![]() Breast cancer cells line MDA-MB-231 were treated with the indicated concentrations of ENMD-2076.
|
|
S8032 |
PRT062607 (P505-15) HClPRT062607 (P505-15, BIIB057, PRT-2607)是一种新型的,高度选择性Syk抑制剂,无细胞试验中IC50为1 nM,作用于Syk比作用于Fgr,PAK5,Lyn,FAK,Pyk2, FLT3, MLK1 和Zap70选择性高80倍以上。 |
![]() ![]() Dectin-1 is involved in activation of NLRP3-inflammasome by Malassezia spp. IL-1b secretion from mature human mono-DCs incubated with Syk-inhibitors (piceatannol, R406 or P505), 1 h prior to exposure to medium, MSU, b-glucan, nigericin or live M. furfur (MOI = 10) was determined after 6 h by ELISA.
|
|
S7008 |
PP2PP2 (AG 1879, AGL 1879) 是一种Src家族激酶抑制剂,有效抑制Lck/Fyn,无细胞试验中IC50为4 nM/5 nM,作用于EGFR效果低100倍左右,对ZAP-70,JAK2和PKA没有活性。 |
![]() ![]() Inhibition of PLCG1 phosphorylation by the silencing of DopEcR, ErGPCR, and Gq and the addition of inhibitors of RTK and Src. 5 µM SU6668 (RTK inhibitor) and 20 µM PP2 (Src inhibitor) were added to the cells for 30 min treatment before the 20E stimulation.
|
|
S2622 |
PP121PP121是一种作用于PDGFR, Hck, mTOR, VEGFR2, Src和Abl的多靶点抑制剂,IC50分别为2 nM, 8 nM, 10 nM, 12 nM, 14 nM和18 nM,也抑制DNA-PK,IC50为60 nM。 |
![]() ![]() PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
|
|
S7060 |
PP1PP1 (AGL 1872, EI 275)是一种有效的Src选择性抑制剂,作用于Lck/Fyn时,IC50为5 nM/6 nM。 |
![]() ![]() Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined as described for inhibitors at indicated times in the presence or absence of the kinase inhibitor PP1. The percent change in FITC-dextran over controls is presented as a measure of EC monolayer permeability. Data are derived from two independent experiments performed in triplicate with comparable results.
|
|
S4921 |
MNS (3,4-Methylenedioxy-β-nitrostyrene)MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)是一种酪氨酸激酶抑制剂,抑制Syk, Src和p97, IC50分别为2.5 μM, 29.3 μM和1.7 μM。 |
![]() ![]() WT mouse primary macrophages were untreated as control (lane 1) or treated with 0.1μg/ml E. coli LPS (lane 5-8), 10μM E-64 (lane 2 and 6), 250μM PMSF (lane 3 and 7), or 20μM MNS (lane 4 and 8). The cells were continuously cultured for 16 hrs. Extracts from whole cells or nuclei were separately purified and subjected to WB analysis with antibody against pERK2, LITAF, or actin/tubulin as control.
|
|
S7565 |
WH-4-023WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) 是一种有效的,口服具有活性的Lck/Src抑制剂,无细胞试验中IC50分别为2 nM 和 6 nM。对p38α和KDR的选择性低300倍以上,还能有效抑制SIK(对SIK1、2、3的IC50分别为10、22、60 nM)。 |
![]() ![]() (G-I) WB analysis of total LCK, LCK Y505, and Src Y416 expression in ALL-SIL, CCRF-CEM, and TALL-1. Cells were treated with DMSO only (Ctrl), dasatinib, bosutinib, nintedanib, or WH-4-023 overnight at the compound concentrations corresponding to the GI50 at 48 hr. Bos, bosutinib; Das, dasatinib; Nint, nintedanib; WH, WH-4-023.
|
|
S3226 |
Dehydroabietic acidDehydroabietic acid (DAA, DHAA) 是一种天然的二萜树脂酸,衍生自针叶植物(如 Pinus 和 Picea)通过抑制 Src、Syk 和 TAK1 介导的通路来产生抗炎活性。 |
||
S0918 |
Ginkgolic acid C17:1Ginkgolic acid C17:1 (GAC 17:1) 通过废除上游的 JAK2 和 Src 来抑制 STAT3 的组成性激活。Ginkgolic acid C17:1 可以诱导 PTEN 和 SHP-1 的大量表达。Ginkgolic acid C17:1 诱导肿瘤细胞凋亡。 |
||
S5254 |
Dasatinib hydrochlorideDasatinib hydrochloride (BMS-354825) is the hydrochloride salt form of dasatinib, an inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. |
||
S0020 |
RK 24466RK-24466 (KIN 001-51, Lck inhibitor C 8863, C8863)是一种有效的、选择性的 Lck 抑制剂,可抑制人Lck激酶的两种构建体,lck (64-509)和lckcd,对应的IC50值分别为小于0.001 μM和0.002 μM。 |
||
S6500 |
KX1-004KX1-004是一种非ATP竞争性的Src protein tyrosine kinase抑制剂,对Src-PTK的IC50值为40 μM。 |
||
S5548 |
7-Hydroxy-4-chromone7-Hydroxychromone is an inhibitor of Src kinase with IC50 of <300 μM. |
||
S8518 |
AD80AD80,一种多激酶抑制剂,对人源RET (c-RET)、BRAF、S6K和SRC活性较强,但对mTOR的活性比AD57或AD58弱。其对RET (c-RET)的IC50值为4 nM。 |
||
S7782 |
Dasatinib MonohydrateDasatinib Monohydrate (BMS-354825)是一种新型有效的多靶点抑制剂,作用于靶点Abl,Src 和 c-Kit,IC50分别为 <1 nM,0.8 nM 和 79 nM。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S8583 |
Repotrectinib (TPX-0005)Repotrectinib (TPX-0005) 是一种新型的ALK/ROS1/TRK抑制剂,对WT ALK、ALK(G1202R)、ALK(L1196M)的IC50分别为1.01 nM、1.26 nM、1.08 nM;同时也是一种有效的SRC抑制剂,IC50为5.3 nM。 |
||
S9643 |
DGY-06-116DGY-06-116 是一种不可逆的、选择性的 Src 的共价抑制剂,对应的IC50值为2.6 nM。 |
||
S2391 |
Quercetin (NSC 9221)Quercetin (NSC 9221, Sophoretin, C.I. 75720)是蔬菜水果和白酒中的天然黄酮类化合物,是一种体外重组Sirt1蛋白的激活剂同时也是PI3K抑制剂,IC50为2.4 – 5.4 μM。Quercetin 可诱导凋亡和保护性的自噬。Phase 4。 |
![]() ![]() After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of Quercetin for 3h,followed by 20-minute stimolation of 100ng/ml EGF. |
|
S7774 |
SU6656SU 6656 是一种选择性 Src 家族激酶抑制剂,对Src,Yes,Lyn,和 Fyn 的 IC50 分别为 280 nM,20 nM,130 nM,和 170 nM。 |
![]() ![]() (B) IP3 levels measured by ELISA in CD36OE and vector control of HepG2.2.15 and HepAD38 cells (n = 3) (*P < 0.05). (C) Src kinase inhibitor (SU6656) decreases cytosolic Ca2+ in CD36OE of HepG2.2.15 and HepAD38 cells. SU6656 or vehicle controls (DMSO) were added to the CD36OE of HepG2.2.15 and HepAD38 cells for 24 h, Cytosolic Ca2+ was measured after treatment using flow cytometry (n = 3) (*** p < 0.001). (D) Src kinase inhibitor (SU6656) overrides the higher HBV replication induced by CD36 overexpression. SU6656 or vehicle controls (DMSO) were added to the CD36 overexpression of HepG2.2.15 and HepAD38 cells for 96 h. HBV DNA were extracted and detected by real-time PCR (n = 4). (**P < 0.01 and*** p < 0.001). |
|
S6567 |
Src Inhibitor 1Src Inhibitor 1是Src和Lck的竞争性抑制剂,IC50分别为44 nM和88 nM。它也能抑制Csk和Yes。 |
||
S7743 |
CCT196969CCT196969是一种新型的、具有口服活性的pan-RAF抑制剂,同时具有抑制SRC的活性。它还能抑制LCK和p38 MAPKs。 |
||
S5617 |
Myristic AcidMyristic acid (Tetradecanoic acid) is a fatty acid that occurs naturally in some foods. Myristic acid inhibits the phosphorylation of poly E4Y by Src with an Ki of 35 μM. |
||
S0791 |
eCF506eCF506 是一种有效的、选择性的和口服生物利用的 Src tyrosine kinase 抑制剂,其IC50值小于0.5 nM。 |
||
S8161 |
ON123300ON123300是有效的多靶点激酶抑制剂,对CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), Fyn的IC50分别为3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM和11nM。 |
||
S6060 |
HPK1-IN-2HPK1-IN-2 是一种有效的和口服活性的 hematopoietic progenitor kinase-1 (HPK1, a serine/threonine Ste20-related protein kinase)、Lck 和 Flt3 的抑制剂,其IC50值分别为 <0.05 μM、<0.5 μM 和 <0.05 μM。HPK1-IN-2 具有抗肿瘤的活性。 |
||
S2213 |
AMG-47aAMG-47a是一种有效的、非选择性的 Lck kinase 抑制剂,IC50为3.4 uM,它还可抑制T细胞增殖。AMG-47a在抗CD3诱导的小鼠白介素2(IL-2)生产过程中表现出11mg/kg的抗炎活性(ED50)。 |
||
S1272 |
XL228XL228 是一种 protein kinase 的抑制剂,对于野生型ABL kinase、ABL T315I、Aurora A、IGF-1R、SRC 和 LYN的IC50值分别为5 nM、1.4 nM、3.1 nM、1.6 nM、6.1 nM和2 nM。 |
||
S2642 |
1-Naphthyl PP1(1-NA-PP1)1-Naphthyl PP1 (1-NA-PP 1)是一种高度选择性的、有效的 pan-PKD 抑制剂,对于PKD1、PKD2和PKD3的IC50值分别为154.6 nM、133.4 nM和109.4 nM。1-Naphthyl PP1是 Src family kinases (v-Src, c-Fyn) 和 the tyrosine kinase c-Abl 的选择性抑制剂, 对于v-Src、c-Fyn、c-Abl、CDK2和CAMK II的IC50值分别为1.0 μM、 0.6 μM、0.6 μM、18 μM 和 22 μM。 |
||
S8706 |
UM-164UM-164是一种高度有效的c-Src/p38双重抑制剂,对c-Src的结合常数Kd值为2.7 nM,也能抑制p38α和p38β。 |
目录号 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S8321 |
MLR-1023MLR-1023 (Tolimidone, CP-26154)是Lyn kinase 激活剂,也是一种新型的insulin receptor 增强剂,在具有2型糖尿病的动物模型中使得葡萄糖稳态快速起效、并持久改善。 |